2025 United States Ai-Based Clinical Trials Revenue Opportunities Report
Description
The 2025 United States Ai-Based Clinical Trials Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively integrating AI in clinical trials in the United States are IQVIA, Syneos Health, Fortrea, and Medidata. IQVIA leads globally with advanced analytics, technology solutions, and comprehensive clinical research services, generating over $15 billion in revenue in 2024, underscoring its dominant presence in the U.S. clinical trial AI space. Syneos Health specializes in late-stage clinical trials with a strong emphasis on integrated solutions from early development through commercialization. Fortrea, spun off from Labcorp, focuses on clinical trial management with strategic investments supporting growth as a pure-play CRO. Medidata leverages AI-powered analytics to provide real-time performance metrics, predictive modeling, and trial optimization solutions tailored to biopharmaceutical companies.
In addition to these, companies like AiCure, Phesi, and Unlearn.ai also contribute advanced AI technologies for patient engagement, site selection, and trial efficiency improvements but with smaller scale compared to the top four. IQVIA and Medidata stand out for delivering AI capabilities that streamline trial site selection, enrollment, and execution, while Syneos and Fortrea excel in operational scale and trial stage focus. These firms represent the core of AI-driven innovation in U.S. clinical trials, advancing data-driven insights, accelerating timelines, and enhancing patient outcomes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively integrating AI in clinical trials in the United States are IQVIA, Syneos Health, Fortrea, and Medidata. IQVIA leads globally with advanced analytics, technology solutions, and comprehensive clinical research services, generating over $15 billion in revenue in 2024, underscoring its dominant presence in the U.S. clinical trial AI space. Syneos Health specializes in late-stage clinical trials with a strong emphasis on integrated solutions from early development through commercialization. Fortrea, spun off from Labcorp, focuses on clinical trial management with strategic investments supporting growth as a pure-play CRO. Medidata leverages AI-powered analytics to provide real-time performance metrics, predictive modeling, and trial optimization solutions tailored to biopharmaceutical companies.
In addition to these, companies like AiCure, Phesi, and Unlearn.ai also contribute advanced AI technologies for patient engagement, site selection, and trial efficiency improvements but with smaller scale compared to the top four. IQVIA and Medidata stand out for delivering AI capabilities that streamline trial site selection, enrollment, and execution, while Syneos and Fortrea excel in operational scale and trial stage focus. These firms represent the core of AI-driven innovation in U.S. clinical trials, advancing data-driven insights, accelerating timelines, and enhancing patient outcomes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
